在COVID-19后的状态下治疗疲劳和心理症状的多尼佩齐尔:一项随机临床试验
Kensuke Nakamura1, Kazuhiro Kondo2, Naomi Oka3
1Department of Critical Care Medicine, Yokohama City University Hospital, Yokohama, Japan.
JAMA network open
|March 17, 2025
概括
在COVID-19后病情的患者中,多尼佩西尔没有显著改善疲劳或心理症状. 需要进一步的研究,以找到有效的治疗长期COVID症状.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 传染性疾病 传染性疾病
背景情况:
- 后COVID-19状态 (长期COVID) 经常导致衰弱的疲劳,可能与脑内炎症和降低的乙胆水平有关.
- 乙胆酶抑制剂,如多内佩西尔,正在作为治疗长期COVID症状的治疗策略进行研究.
研究的目的:
- 评估多尼佩西尔化在缓解COVID-19后情况的成年人疲劳和心理症状方面的疗效.
- 评估多尼佩西尔对与长期COVID相关的各种患者报告结果的影响.
主要方法:
- 一个多中心,双盲,随机的临床试验,涉及110名患有COVID-19后疾病和显著疲劳的成年患者.
- 参与者接受了多尼佩西尔 (逐渐增加剂量) 或安慰剂三周,结果在治疗开始后的三周和八周进行评估.
主要成果:
- 与安慰剂相比,3周后,多尼佩西尔在疲劳得分 (卡尔德疲劳量表) 中没有统计学上显著的改善 (平均差异为0.34,P=.79).
- 二次结局,包括焦虑,抑郁和生活质量,在三周和八周的多尼佩西尔和安慰剂组之间也是相似的.
- 在任何治疗组中都没有报告任何严重不良事件.
结论:
- 在这种患者群体中,没有发现多尼佩西尔化水在治疗疲劳或与COVID-19后状况相关的心理症状方面有效.
- 该研究强调了开发和测试长期COVID的新疗法的必要性,并强调了持续临床试验的重要性.
相关概念视频
01:22Alzheimer's Disease: Treatment
141
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
141
01:21Fatigue
169
Fatigue occurs when materials rupture under repeated or fluctuating loads, even at stress levels far below their static breaking strength. It typically results in brittle failure, even for ductile materials. It is a critical consideration in designing machines and structural components subjected to repetitive or varying loads. The nature of these loadings can range from fluctuating loads like unbalanced pump impellers causing vibrations to repeatedly bending a thin steel rod wire back and forth...
169
01:24Parkinson's Disease: Treatment
174
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
174
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
88
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
88
01:23Antidepressant Drugs: MAOIs and Other Agents
174
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
174
01:20Myasthenia Gravis: Overview and Treatment
1.1K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.1K